Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 228

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 228
---
.

Our
Common Stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all if investors need to sell
shares to raise money or otherwise desire to liquidate their shares.

To
date, there have been many days on which limited trading of our Common Stock took place. We cannot predict the extent to which investors’
interests will lead to an active trading market for our Common Stock or whether the market price of our Common Stock will be volatile.
If an active trading market does not develop, investors may have difficulty selling our Common Stock. We are likely to be too small to
attract the interest of many brokerage firms and analysts. We cannot give investors any assurance that an active public trading market
for our Common Stock will develop or be sustained. The market price of our Common Stock could be subject to wide fluctuations in response
to quarterly variations in our revenues and operating expenses, announcements of new products or services by us, significant sales of
our Common Stock, including “short” sales, the operating and stock price performance of other companies that investors may
deem comparable to us, and news reports relating to trends in our markets or general economic conditions.

 48 

An
investment in our Company may involve tax implications, and you are encouraged to consult your own advisors as neither we nor any related
party is offering any tax assurances or guidance regarding our Company or your investment.

An
investment in our Company generally, involves complex federal, state, and local income tax considerations. Neither the Internal Revenue
Service nor any state or local taxing authority has reviewed the transactions described herein and may take different positions than
the ones contemplated by management. You are strongly urged to consult your own tax and other advisors prior to investing, as neither
we nor any of our officers, directors, or related parties can offer tax or similar advice, nor are any such persons making any representations
and warranties regarding such matters.

Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Under
Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally
defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to
use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its
post-change income may be limited. We